Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
| Revenue (TTM) | $116.26M |
| Gross Profit (TTM) | $68.12M |
| EBITDA | $-5.27M |
| Operating Margin | -13.20% |
| Return on Equity | -7.85% |
| Return on Assets | -3.60% |
| Revenue/Share (TTM) | $8.22 |
| Book Value | $10.03 |
| Price-to-Book | 1.49 |
| Price-to-Sales (TTM) | 1.73 |
| EV/Revenue | 1.589 |
| EV/EBITDA | 175.12 |
| Quarterly Earnings Growth (YoY) | -50.50% |
| Quarterly Revenue Growth (YoY) | 13.20% |
| Shares Outstanding | $13.31M |
| Float | $11.21M |
| % Insiders | 6.42% |
| % Institutions | 94.80% |
Volatility is currently contracting
Anika Therapeutics NASDAQ: ANIK reported higher second-quarter revenue, expanded gross margin and its strongest adjusted EBITDA performance since 2020, as international commercial growth and manufacturing improvements supported profitability.
BEDFORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2026 financial results before the opening of the market on Wednesday, July 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation.
Anika Therapeutics is refocusing on HA-based OA pain management and regenerative orthopedic products. The main drivers here are Monovisc, Orthovisc, and Integrity. Particularly, ANIK's Integrity received 510(k) clearance in 2023. Recently, its revenues have more than doubled in 2025. Hyalofast and Cingal also offer interesting regulatory catalysts, but they bring FDA timing and approval risks.
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing Delivered 64% gross margin, +8 points year over year, driven by improved operational execution Operational transformation generating early wins, delivering $4 million of adjusted EBITDA BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ANIK and any ticker you trade — then tracks every position and per-strategy win rate.
